Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Intraocular Lymphoma × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 42 Central Nervous System Neoplasms 21 Brain Neoplasms 21 Glioma 14 Astrocytoma 14 Medulloblastoma 8 Oligodendroglioma 7 Lymphoma 7 Recurrence 6 Neoplasms 6 Gliosarcoma 6 Spinal Cord Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Lymphoma, AIDS-Related 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Ependymoma 2 Burkitt Lymphoma 2 Uveal Melanoma 1 Solid Tumor 1 Sarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Optic Nerve Glioma 1 Neuroectodermal Tumors 1 Neoplasms, Plasma Cell 1 Neoplasm Recurrence, Local 1

Interventions

Rituximab 12 Cyclophosphamide 11 Peripheral Blood Stem Cell Transplantation 10 fludarabine phosphate 8 Filgrastim 8 Cyclosporine 8 Whole-Body Irradiation 7 Methotrexate 7 Etoposide 7 Mycophenolic Acid 6 Lenalidomide 6 Radiotherapy 5 Cytarabine 5 Tacrolimus 4 Dexamethasone 4 Antilymphocyte Serum 4 Vorinostat 3 Thiotepa 3 Melphalan 3 Granulocyte Colony-Stimulating Factor 3 Dasatinib 3 Carboplatin 3 Busulfan 3 Bortezomib 3 tanespimycin 2 pegfilgrastim 2 laromustine 2 ibrutinib 2 etoposide phosphate 2 entinostat 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00074191 2017-04-21

Protocol-A

OHSU Knight Cancer Institute

Phase 2 Completed

Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡